In-hospital antibiotic use for severe chronic obstructive pulmonary disease exacerbations: a retrospective observational study.
Antibiotics
Chronic obstructive pulmonary disease
Severe exacerbations
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
25 Apr 2023
25 Apr 2023
Historique:
received:
11
01
2023
accepted:
08
04
2023
medline:
27
4
2023
pubmed:
26
4
2023
entrez:
25
4
2023
Statut:
epublish
Résumé
The use of antibiotics in mild to severe acute exacerbations of chronic obstructive pulmonary disease (COPD) remains controversial. To explore in-hospital antibiotic use in severe acute exacerbations of COPD (AECOPD), to analyze determinants of in-hospital antibiotic use, and to investigate its association with hospital length of stay (LOS) and in-hospital mortality. A retrospective, observational study was conducted in Ghent University Hospital. Severe AECOPD were defined as hospitalizations for AECOPD (ICD-10 J44.0 and J44.1) discharged between 2016 and 2021. Patients with a concomitant diagnosis of pneumonia or 'pure' asthma were excluded. An alluvial plot was used to describe antibiotic treatment patterns. Logistic regression analyses identified determinants of in-hospital antibiotic use. Cox proportional hazards regression analyses were used to compare time to discharge alive and time to in-hospital death between antibiotic-treated and non-antibiotic-treated AECOPD patients. In total, 431 AECOPD patients (mean age 70 years, 63% males) were included. More than two-thirds (68%) of patients were treated with antibiotics, mainly amoxicillin-clavulanic acid. In multivariable analysis, several patient-related variables (age, body mass index (BMI), cancer), treatment-related variables (maintenance azithromycin, theophylline), clinical variables (sputum volume and body temperature) and laboratory results (C-reactive protein (CRP) levels) were associated with in-hospital antibiotic use independent of sputum purulence, neutrophil counts, inhaled corticosteroids and intensive care unit of which CRP level was the strongest determinant. The median hospital LOS was significantly longer in antibiotic-treated patients (6 days [4-10]) compared to non-antibiotic-treated patients (4 days [2-7]) (p < 0.001, Log rank test). This was indicated by a reduced probability of hospital discharge even after adjustment for age, sputum purulence, BMI, in-hospital systemic corticosteroid use and forced expiratory volume in one second (FEV In this observational study in a Belgian tertiary hospital, in-hospital antibiotic use among patients with severe AECOPD was determined by the symptom severity of the exacerbation and the underlying COPD severity as recommended by the guidelines, but also by patient-related variables. Moreover, in-hospital antibiotic use was associated with a longer hospital stay, which may be linked to their disease severity, slower response to treatment or 'harm' due to antibiotics. Number: B670201939030; date of registration: March 5, 2019.
Sections du résumé
BACKGROUND
BACKGROUND
The use of antibiotics in mild to severe acute exacerbations of chronic obstructive pulmonary disease (COPD) remains controversial.
AIM
OBJECTIVE
To explore in-hospital antibiotic use in severe acute exacerbations of COPD (AECOPD), to analyze determinants of in-hospital antibiotic use, and to investigate its association with hospital length of stay (LOS) and in-hospital mortality.
METHODS
METHODS
A retrospective, observational study was conducted in Ghent University Hospital. Severe AECOPD were defined as hospitalizations for AECOPD (ICD-10 J44.0 and J44.1) discharged between 2016 and 2021. Patients with a concomitant diagnosis of pneumonia or 'pure' asthma were excluded. An alluvial plot was used to describe antibiotic treatment patterns. Logistic regression analyses identified determinants of in-hospital antibiotic use. Cox proportional hazards regression analyses were used to compare time to discharge alive and time to in-hospital death between antibiotic-treated and non-antibiotic-treated AECOPD patients.
RESULTS
RESULTS
In total, 431 AECOPD patients (mean age 70 years, 63% males) were included. More than two-thirds (68%) of patients were treated with antibiotics, mainly amoxicillin-clavulanic acid. In multivariable analysis, several patient-related variables (age, body mass index (BMI), cancer), treatment-related variables (maintenance azithromycin, theophylline), clinical variables (sputum volume and body temperature) and laboratory results (C-reactive protein (CRP) levels) were associated with in-hospital antibiotic use independent of sputum purulence, neutrophil counts, inhaled corticosteroids and intensive care unit of which CRP level was the strongest determinant. The median hospital LOS was significantly longer in antibiotic-treated patients (6 days [4-10]) compared to non-antibiotic-treated patients (4 days [2-7]) (p < 0.001, Log rank test). This was indicated by a reduced probability of hospital discharge even after adjustment for age, sputum purulence, BMI, in-hospital systemic corticosteroid use and forced expiratory volume in one second (FEV
CONCLUSIONS
CONCLUSIONS
In this observational study in a Belgian tertiary hospital, in-hospital antibiotic use among patients with severe AECOPD was determined by the symptom severity of the exacerbation and the underlying COPD severity as recommended by the guidelines, but also by patient-related variables. Moreover, in-hospital antibiotic use was associated with a longer hospital stay, which may be linked to their disease severity, slower response to treatment or 'harm' due to antibiotics.
TRIAL REGISTRATION
BACKGROUND
Number: B670201939030; date of registration: March 5, 2019.
Identifiants
pubmed: 37098509
doi: 10.1186/s12890-023-02426-3
pii: 10.1186/s12890-023-02426-3
pmc: PMC10127022
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
138Informations de copyright
© 2023. The Author(s).
Références
Infection. 2020 Feb;48(1):19-35
pubmed: 31482316
ERJ Open Res. 2016 Mar 05;2(1):
pubmed: 27730166
Ann Intern Med. 1987 Feb;106(2):196-204
pubmed: 3492164
BMJ. 2017 Aug 4;358:j3402
pubmed: 28778936
J Gen Intern Med. 2022 Dec;37(16):4183-4188
pubmed: 35316516
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1488-1502
pubmed: 33332995
Respirology. 2009 Nov;14(8):1114-20
pubmed: 19761538
Ther Adv Respir Dis. 2013 Jun;7(3):131-7
pubmed: 23325784
Int J Mol Sci. 2017 Jun 23;18(7):
pubmed: 28644389
BMC Pulm Med. 2022 May 13;22(1):194
pubmed: 35549921
Cochrane Database Syst Rev. 2018 Oct 29;10:CD010257
pubmed: 30371937
N Engl J Med. 2008 Nov 27;359(22):2355-65
pubmed: 19038881
Am J Respir Crit Care Med. 2019 Oct 1;200(7):857-868
pubmed: 31046405
Lancet. 2007 Sep 1;370(9589):786-96
pubmed: 17765528
J Antimicrob Chemother. 2018 Jun 1;73(suppl_6):vi59-vi66
pubmed: 29878220
Ann Pharmacother. 2019 Feb;53(2):144-150
pubmed: 30175589
Lancet. 2001 Dec 15;358(9298):2020-5
pubmed: 11755608
COPD. 2020 Dec;17(6):706-710
pubmed: 33169617
Int J Chron Obstruct Pulmon Dis. 2015 Oct 20;10:2257-63
pubmed: 26527871
BMC Pulm Med. 2015 Jan 27;15:5
pubmed: 25623589
PLoS One. 2015 Apr 23;10(4):e0124374
pubmed: 25905726
Chest. 2016 Aug;150(2):320-8
pubmed: 26851799
Br J Gen Pract. 2021 Mar 26;71(705):e266-e272
pubmed: 33657007
Eur Respir J. 2013 Feb;41(2):270-6
pubmed: 22599361
Allergy. 2020 Aug;75(8):2111-2115
pubmed: 32243598
Ann Am Thorac Soc. 2013 Apr;10(2):81-9
pubmed: 23607835
J Infect. 2013 Dec;67(6):497-515
pubmed: 23973659
Infect Control Hosp Epidemiol. 2017 Aug;38(8):993-997
pubmed: 28560946
Eur Respir J. 2019 May 23;53(5):
pubmed: 30880285
COPD. 2020 Jun;17(3):311-317
pubmed: 32456479
Am J Respir Med. 2003;2(6):459-68
pubmed: 14719985
Chest. 2013 Jan;143(1):82-90
pubmed: 22797691
BMJ Open Respir Res. 2020 Feb;7(1):
pubmed: 32075781